Atlas Capital Markets

Eniblock is helping enterprises, brands, and creators build seamless, robust & scalable Web3 experiences, onboard their customers with ease, engage with their communities and scale their business to millions of users.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing innovative ophthalmic therapies aimed at preserving vision in patients with retinal vascular disorders. The company targets conditions such as diabetic macular edema, which is the leading cause of vision loss among diabetic patients, as well as wet age-related macular degeneration and retinal vein occlusion. Through its advanced research and development initiatives, Oxurion seeks to create next-generation treatments that enhance the standard of care for these debilitating eye diseases.

Biophytis SA is a clinical-stage biotechnology company headquartered in Paris, France, dedicated to developing therapeutics aimed at slowing the degenerative processes associated with aging and enhancing functional outcomes for patients with age-related diseases. The company is focused on activating key biological resilience pathways that may protect against the effects of various biological and environmental stresses linked to these diseases. Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule designed for treating neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. Additionally, its second candidate, Macuneos (BIO201), targets retinal diseases, including age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon to further the development of Sarconeos. Since its founding in 2006, Biophytis has aimed to position itself as a leader in the emerging field of aging science by providing innovative therapies for patients with limited treatment options.